SANOFI-AVENTIS (EPA:SAN) ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)
Transparency directive : regulatory news
24/02/2023 17:16
SANOFI-AVENTIS's latest news
08/06/2023 23:19
01/06/2023 07:30
21/05/2023 20:17
17/05/2023 22:01
12/05/2023 10:50
04/05/2023 08:00
27/04/2023 14:40
19/04/2023 21:05
11/04/2023 08:00
10/04/2023 22:15
Other stories
09/06/2023 22:04
09/06/2023 21:52
09/06/2023 13:54
09/06/2023 17:57
09/06/2023 15:48
09/06/2023 06:01
09/06/2023 19:00
09/06/2023 14:21
09/06/2023 17:06
09/06/2023 16:27
09/06/2023 13:01
09/06/2023 15:15
09/06/2023 16:15
09/06/2023 16:41
09/06/2023 21:50
09/06/2023 17:56
09/06/2023 14:43
09/06/2023 20:33
09/06/2023 07:00
08/06/2023 21:36
08/06/2023 22:06
09/06/2023 04:55
09/06/2023 18:25
09/06/2023 16:25
09/06/2023 13:03
09/06/2023 15:38
09/06/2023 21:26
09/06/2023 23:15
09/06/2023 18:00
09/06/2023 18:09
09/06/2023 10:37
09/06/2023 20:14
08/06/2023 20:47
09/06/2023 20:25
09/06/2023 12:54
09/06/2023 11:26
Eight warning signs to watch out for as cases of medieval disease surge in UK - Gloucestershire Live
09/06/2023 05:57
09/06/2023 18:48